Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotransplant(BTRN) -- Ignore unavailable to you. Want to Upgrade?

To: Arthur Radley who wrote (1108)	11/12/2001 9:29:33 PM
From: Arthur Radley	Read Replies (1) \| Respond to of 1475

part 7 by: soldier30 11/12/01 09:00 pm Msg: 1298 of 1302 In our view, the initial data reported in the three ASH abstracts supports the utility of the TCell-HDM system for use as a tool to decrease the occurrence of GvHD and the use of the AlloMune System for the treatment of hematologic cancers. In the first abstract, investigators examined the use of CD8 T-cell depletion in an 18 patient study as a means to decrease the rate of GvHD in patients receiving donor lymphocyte infusions (DLI). Specifically, this randomized trial examined the impact of CD8 T-cell depletion on GvHD and graft versus tumor responses. Importantly, the results from the study indicate that CD8 T-cell depletion reduces the incidence of GvHD associated with DLI without compromising anti-tumor activity or immunologic recovery. We are encouraged by the initial results reported and believe they support the use of BioTransplant's TCell-HDM system in this therapeutic setting. Two additional abstracts report results using a prototype AlloMune Systems for the treatment of refractory non-Hodgkin's lymphoma (NHL) in a 69 patient study and refractory B cell lymphoma (BCL) in a 20 patient study. In the NHL study, of 69 patients, 46 received a stem cell transplant (SCT) from an HLA-matched donor, while 23 received an HLA-mismatched donor transplant. Initial mixed chimerism (MC) was demonstrated in all evaluable patients. Forty-nine patients maintained MC or converted to full donor chimerism (FDC). Importantly, 17 of 49 (35%) patients who maintained donor chimerism achieved a complete response (CR) or CR with residual radiologic abnormality compared with four of 20 (20%) patients who lost donor chimerism. The BCL study, evaluated non-myeloablative bone marrow transplantation in 20 patients with advanced BCL. The results indicate that 8 of 19 evaluable patients achieved a response (5 CR, 3 PR) including 3 of 10 HLA matched patients and 5 of 10 HLA mismatched patients. Additionally, five patients were alive, and progression free at 13 to 52 months post-transplant. We are encouraged by these preliminary results and believe they demonstrate the utility of the AlloMune System as a method for the treatment of refractory hematologic cancers.